SRDX - サ―モディクス （Surmodics Inc.） サ―モディクスSRDXのチャート
SRDXの企業情報
| symbol | SRDx |
|---|---|
| 会社名 | Surmodics Inc （サ―モディクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 サーモディクス(SurModics Inc.)は医療業界向けに医療機器と体外診断技術を提供する。同社は2事業セグメントを運営する。医療機器部門は医療機器のアクセス、送達性及び予測可能な配備を向上させる表面改質コーティング技術と、国際心臓学および末梢バルーン設計・開発・製造、並びに医療デバイスの表面からの部位特異的薬物送達を提供する薬物送達コーティング技術を含む。インビトロ診断部門は、インビトロ診断イムノアッセイおよび分子検査のためのコンポーネントを製造または販売し、診断、生物医学研究、ライフサイエンス市場への表面コーティングの製造・販売を行い、タンパク質安定化試薬、基質、抗原及び表面コーティングを提供する。 サ―モディクスは、米国の医療器具表面修正ソリュ―ション会社。事業は2部門で構成される。医療機器部門は、医療機器や薬物送達コ―ティング技術の開発を行う。対外診断技術部門は、分子検査および生物医学研究アプリケ―ションの技術開発を行う。本社は、ミネソタ州エデンプレ―リ―。 Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics' website is not part of this press release or part of any filings that the company makes with the SEC. |
| 本社所在地 | 9924 West 74th Street Eden Prairie MN 55344 USA |
| 代表者氏名 | Susan E. Knight スーザンE.ナイト |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 952-500-7000 |
| 設立年月日 | 29007 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1998年 |
| 従業員数 | 257人 |
| url | www.surmodics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/srdx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 8.20500 |
| 終値（lastsale） | 64.34 |
| 時価総額（marketcap） | 859041429.28 |
| 時価総額 | 時価総額（百万ドル） 828.86680 |
| 売上高 | 売上高（百万ドル） 78.35600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 766.83380 |
| 当期純利益 | 当期純利益（百万ドル） -1.10400 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 SurModics Inc. revenues increased 10% to $58.3M. Net loss before extraordinary items totaled $1.5M vs. income of $3.5M. Revenues reflect Medical Device segment increase of 11% to $43.5M Diagnostics/In Vitro segment increase of 7% to $14.8M. Net loss reflects Medical Device segment loss totaling $6.4M vs. income of $6.6M Corporate segment loss increase of 7% to $6.3M. |
SRDXのテクニカル分析
SRDXのニュース
Surmodics stock surges 10% on FDA feedback for drug-coated balloon filing 2023/03/28 16:23:16 Seeking Alpha
Surmodics (SRDX) stock rose after the company said it received feedback from the FDA for an application seeking approval of SurVeil. Read more here
Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil Drug-Coated Balloon 2023/03/28 13:25:00 Wallstreet:Online
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it has received formal feedback from the Food and Drug Administration (FDA; the Agency) related to its proposed approach to submit an amended premarket approval (PMA) application for the SurVeil drug-coated balloon (DCB). Following the receipt
Trading Surmodics $SRDX With Integrated Risk Controls 2023/03/12 11:45:00 Stock Traders Daily
Trading Surmodics SRDX With Integrated Risk Controls
Surmodics to Participate in Upcoming Investor Conferences in March 2023/03/08 13:30:00 Business Wire
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #InVitroDiagnostic--Management will make a presentation to the investment community at the Oppenheimer Healthcare Conference on Wednesday, March 15, at 9:40 a.m. CT.
Surmodics downgraded at Needham on uncertainty over drug-coated balloon 2023/02/13 17:29:22 Seeking Alpha
Surmodics, Inc. (SRDX) lost sharply on Monday after Needham downgraded it to Hold from Buy, citing uncertain prospects for its drug-coated balloon SurVeil. Read the full story here.
Surmodics, Inc. (SRDX) Q4 2022 Earnings Call Transcript 2022/11/13 01:45:03 Seeking Alpha
Surmodics, Inc. (NASDAQ:NASDAQ:SRDX) Q4 2022 Earnings Conference Call November 09, 2022, 10:00 ET Company Participants Gary Maharaj - CEO, President & Director Timothy Arens - SVP,…
Surmodics, Inc. 2022 Q4 - Results - Earnings Call Presentation 2022/11/13 01:44:38 Seeking Alpha
The following slide deck was published by Surmodics, Inc.
Surmodics Non-GAAP EPS of -$0.26 beats by $0.19, revenue of $25.99M beats by $1.9M 2022/11/09 12:46:53 Seeking Alpha
Surmodics press release (SRDX): Q4 Non-GAAP EPS of -$0.26 beats by $0.19.Revenue of $25.99M (+8.4% Y/Y) beats by $1.9M.Guidance: Surmodics expects fiscal year 2023 total revenue…
Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance 2022/11/09 12:00:00 Business Wire
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces the Fiscal Year 2023 Financial Guidance
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th 2022/10/28 11:30:00 Business Wire
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
Surmodics Non-GAAP EPS of -$0.13, revenue of $23M; reaffirms full year guidance 2022/02/03 12:39:17 Seeking Alpha
Surmodics press release (SRDX): FQ1 Non-GAAP EPS of -$0.13.Revenue of $23M (+3.1% Y/Y).Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million vs
Surmodics, Inc. (NASDAQ:SRDX) Shares Sold by New York State Teachers Retirement System 2021/12/23 09:22:47 Transcript Daily
New York State Teachers Retirement System reduced its position in Surmodics, Inc. (NASDAQ:SRDX) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,326 shares of the companys stock after selling 500 shares during the quarter. New York []
Surmodics (NASDAQ:SRDX) Shares Gap Up to $44.84 2021/12/09 09:22:41 Transcript Daily
Shares of Surmodics, Inc. (NASDAQ:SRDX) gapped up before the market opened on Tuesday . The stock had previously closed at $44.84, but opened at $47.67. Surmodics shares last traded at $45.99, with a volume of 2 shares. Separately, Needham & Company LLC dropped their price objective on Surmodics from $76.00 to $70.00 and set a []
Assenagon Asset Management S.A. Has $5.76 Million Stock Position in Surmodics, Inc. (NASDAQ:SRDX) 2021/12/06 11:08:43 Dakota Financial News
Assenagon Asset Management S.A. lowered its stake in Surmodics, Inc. (NASDAQ:SRDX) by 2.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 103,586 shares of the companys stock after selling 2,230 shares during the period. Assenagon Asset Management S.A. owned approximately 0.75% of Surmodics worth []
Insider Selling: Surmodics, Inc. (NASDAQ:SRDX) Director Sells 3,475 Shares of Stock 2021/11/29 22:24:42 Transcript Daily
Surmodics, Inc. (NASDAQ:SRDX) Director David Dantzker sold 3,475 shares of Surmodics stock in a transaction on Wednesday, November 24th. The stock was sold at an average price of $47.01, for a total transaction of $163,359.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Shares of SRDX []